Clinical experience with the use of the intestinal antibiotic Rifaximin for celiac disease

Abstract

The article is devoted to new possibilities in the treatment of hereditary intestinal diseases, accompanied by a decrease in kinetic activity or the absence of enteric enzymes, including celiac disease. Despite strict adherence to the elimination diet, some patients develop IBS-like symptoms, which may be caused by a violation of the qualitative and quantitative composition of the intestinal microflora. Dysbiotic disorders play a role in the pathogenesis of the appearance of IBS-like symptoms and complicate the course of celiac disease, which requires the use of antibacterial drugs. The presence of side effects when using systemic antibacterial drugs limits their use. In this regard, the search for ways to correct the intestinal microflora, as well as the study of various approaches to maintaining the intestinal microecology in a state of physiological equilibrium in patients with celiac disease, are relevant for medical science. The article presents a clinical example of the successful and safe use of a drug with low absorption, high antibacterial activity – rifaximin in a patient with celiac disease to correct dysbiotic disorders.